Thrombotic thrombocytopenic purpura and adult onset still's disease

American Journal of the Medical Sciences

Volumn 337, Issue 5, 2009, Pages 373-376

  Gopal, Muralikrishna ^a   Cohn, Charles D ^a   McEntire, Michael R ^a   Alperin, Jack B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

ADAMTS13; Adult onset still's disease; Plasma exchange; Splenectomy; Thrombotic thrombocytopenic purpura

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; PREDNISOLONE; PREDNISONE; VANCOMYCIN; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; CD36 ANTIGEN;

ACUTE KIDNEY FAILURE; ADULT; ADULT ONSET STILL DISEASE; AFRICAN AMERICAN; ANEMIA; ARTHRALGIA; ARTHRITIS; ARTICLE; ARTIFICIAL VENTILATION; BLOOD PRESSURE; BLOOD SMEAR; BODY TEMPERATURE; BONE MARROW BIOPSY; CASE REPORT; CENTRAL VENOUS CATHETER; COMA; COMPUTER ASSISTED TOMOGRAPHY; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; ENZYME ACTIVITY; EXTUBATION; FEVER; GRAND MAL SEIZURE; HAND RADIOGRAPHY; HEART RATE; HEMOLYTIC ANEMIA; HUMAN; HUMAN TISSUE; INTUBATION; JOINT SWELLING; KNEE RADIOGRAPHY; MALE; MENTAL DISEASE; OLIGURIA; PLASMAPHERESIS; POLYARTHRITIS; REMISSION; SPLENECTOMY; STAPHYLOCOCCUS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; ETHNOLOGY; HEMATOLOGY; IMMUNOLOGY; METHODOLOGY; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; ANTIGENS, CD36; HEMATOLOGY; HUMANS; MALE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION; SPLENECTOMY; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 67649103645     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318191436e     Document Type: Article

References (36)

1. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006;46:154-6.
2. Vamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease [see comment]. J Rheumatol 19:424-30.
3. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966;45:139.
4. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
5. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-35.
6. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-8.
7. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979;115:728-30.
8. Yoshida H, Ito K, Kusakari T, et al. Removal of maternal antibodies from a woman with repeated fetal loss due to P blood group incompatibility. Transfusion 1994;34:702-5.
9. Graus F, Abos J, Roquer J, et al. Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes. Neurology 1990;40:1621-3.
10. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
11. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5.
12. George JN. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med 2007;22:82-91.
13. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24:21-4.
14. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925;36:89-93.
15. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-9.
16. Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432-6.
17. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
18. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thormbocytopenic purpura. In: Broudy VC, Berliner N, Larson RA, et al, editors. Hematology 2004. Washington DC: American Society of Hematology; 2004. p. 407-23.
19. Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine 2003;82:27-38.
20. George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21:49-56.
21. Cataland SR, Jin M, Zheng XL, et al. An evaluation of cyclosporine alone for the treatment of early recurrences of thrombotic thrombocytopenic purpura. J Thromb Haemost 2006;4:1162-4.
22. Fontana S, Krcmer Hovinga JA, Lammle B, et al. Treatment of thrombotic thrombocytopenic purpura. Vox Sanguinis 2006;90:245-54.
23. Kappers-KIunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005;130:768-76.
24. Ogawa Y, Mukai M, Gotoh H. A case of thrombotic thrombocytopenic purpura with systemic lupus erythematosus. [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 2006;29:342-7.
25. Kfoury Baz EM, Mahfouz RA, Masri AF. Thrombotic thrombocytopenic purpura in a patient with rheumatoid arthritis treated by plasma exchange. Ther Apher 1999;3:314-6.
26. Sano F, Fukumura T, Arai N, et al. Thrombotic thrombocytopenic purpura associated with myasthenia gravis [Japanese]. Rinsho Ketsueki-Jpn J Clin Hematol 1991;32:255-60.
27. Robert V, Eszto P, Perrotez JL, et al. Treatment by plasma exchange of a thrombotie thrombocytopenic purpura associated to a Still's disease: a case report [French]. Ann Fr Anesth Reanim 2006;25:532-4.
28. Perez MG, Rodwig FR Jr. Chronic relapsing thrombotic thrombocytopenic purpura in adult onset Still's disease. South Med J 2003;96: 46-9.
29. Aiken ML, Ginsberg MH, Byers-Ward V, et al. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on the platelet aggregation and thrombospondin surface expression. Blood 1990;76:2501-9.
30. Lian ECY, Siddiqui FA, Jamieson GA, et al. Platelet agglutinating protein p37 causes platelet agglutination through its binding to membrane glycoprotein IV. Thromb Haemost 1991;65:102-6.
31. Siddiqui FA, Lian ECY. Platelet-agglutinating protein p37 from a thrombotic thrombocytopenic purpura plasma forms complexes with platelet membrane glycoprotein IV (CD36). Biochem Int 1992;27: 485-96.
32. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994;88:816-25.
33. Knowles DM, Tolidjian B, Marboe C, et al. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol 1984;132:2170-3.
34. Swerlick RA, Lee KH, Wick TM, et al. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992;148:78-83.
35. Rosove MH, Bhuta S. Splenectomy and extravascular platelet destruction in thrombotic thrombocytopenic purpura. Arch Intern Med 1985; 145:937-9.
36. Saracco SM, Farhi DC. Splenic pathology in thrombotic thrombocytopenic purpura. Am J Surg Pathol 1990;14:223-9.